PharmaRadar360

Entity and regulatory intelligence

Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

44,831 stories, page 622 of 748

Advanced search

🇺🇸Jul 1CROir.labcorp.comTier 3 · Secondary coverage

Labcorp to Announce Second Quarter 2026 Financial Results on July 30, 2026

Labcorp Drug DevelopmentOriginal source

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

Delaware Judge Tosses Biotech Exec.'s $700M Suit Over Failed IPO

Law.comOriginal source

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

RFK Jr. wants to make it easier to get peptides. FDA scientists disagree.

NBC NewsOriginal source

🌍Jul 1discoverynews.google.comTier 2 · Trade media

Anthropic releases Claude Science, a product aimed at researchers, the pharma industry

statnews.comOriginal source

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

REGENXBIO doses first patient in NAAVIGATE, phase 2b/3 sura-vec trial for diabetic retinopathy

Ophthalmology TimesOriginal source

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

Gerren McHam on the Future of US Pharma Reshoring

Pharmaceutical CommerceOriginal source

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

FDA Approves New TED Drug for Active and Chronic Phases

Review of OptometryOriginal source

🌍Jul 1discoverynews.google.comTier 2 · Trade media

BIO 2026: Biotech Fundraising Rises As Company Pipelines Mature

insights.citeline.comOriginal source

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

FDA Names Seven Participants to Precheck Program | PharmExec

Pharmaceutical ExecutiveOriginal source

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

Ever Supreme Advances Off-the-Shelf CAR-T Therapy CAR001 to Phase IIa After Positive Phase I Safety Review

BioPharma APACOriginal source

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

FDA scientists flag concerns with peptides, the trendy molecules RFK Jr. supports

NPROriginal source

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

UMSOP Professor Richard Dalby Retires After 34 Years of Leadership in Pharmaceutical Sciences

The University of Maryland, BaltimoreOriginal source

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

US FDA declines to approve Unicycive’s kidney disease drug

93.3 The DriveOriginal source

🇺🇸Jul 1Industrybioreference.comTier 1 · Company source

Men’s Health Month: An Opportunity to Strengthen Preventive Care Engagement

BioReference LaboratoriesOriginal source

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

Why Sellas Remains A Strong Sell After Doubling In Price (NASDAQ:SLS)

Seeking AlphaOriginal source

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

DEA, FDA Testify on First Day of Hearing on Marijuana Rescheduling

FilterOriginal source

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

Pharmaceutical company closing Birmingham facility

AL.comOriginal source

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

Buzz On Experimental Drug For Bowel Disease Sets This Biotech Stock Soaring 40%

NDTV ProfitOriginal source

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

FDA lets Philip Morris market Zyn nicotine pouches as less harmful than cigarettes

CNBCOriginal source

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

Candel Therapeutics initiates phase 3 lung cancer trial By Investing.com

Investing.com South AfricaOriginal source

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy Drugs

BenzingaOriginal source

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

Manufacturing Deficiencies Behind FDA's Oxylanthanum Carbonate Rejection

PharmTech.comOriginal source

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

Many pharmaceutical active ingredients can switch to PFAS-free alternatives

News-MedicalOriginal source

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

Anthropic Livestreams AI for Science Pitch as No AI Drug Has Won FDA Approval

Tech TimesOriginal source

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

Candel Therapeutics Stock Gains on Launch of Phase 3 Trial for Lung-Cancer Drug

marketscreener.comOriginal source

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

FDA Selects Seven Pharmaceutical Companies for PreCheck Supply Chain Pilot Program

geneonline.comOriginal source

🌍Jul 1discoverynews.google.comTier 2 · Trade media

EAN 2026: New Fintepla data in Dravet Syndrome and LGS

Pharmaceutical TechnologyOriginal source

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

Pelabresib from MorphoSys AG - late-stage blood cancer drug reshapes the pipeline

AD HOC NEWSOriginal source

🇺🇸Jul 1CDMOagcbio.comTier 2 · Direct publisher

AGC Biologics Expands to Fill-Finish in U.S. Through Strategic Partnership with Pyramid Pharma Services

AGC BiologicsOriginal source

🌍Jul 1discoverynews.google.comTier 3 · Aggregated media

RFK Jr.’s plan to boost peptide access just got more complicated

The Washington PostOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Stoke completes Phase 3 enrollment for Dravet drug study

grafa.comOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Abivax Shares Surge Over 40% as Obefazimod Data Eases Cancer Fears Ahead of FDA Filing

finance.biggo.comOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Seven Companies Selected for FDA Pilot to Strengthen US Drug Supply Chain

Pharmaceutical CommerceOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Imviva Biotech Gains FDA IDE Authorization for clonoSEQ Assay in TENACITY-01 Clinical Trial

citybizOriginal source

🇺🇸Jun 30Researchatlasventure.comTier 2 · Direct publisher

Two Roads Diverged

Atlas VentureOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

4DMT completes enrollment in 4FRONT-2, global phase 3 trial of 4D-150 in wet AMD

Ophthalmology TimesOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Why Is Unicycive Therapeutics Stock Falling Tuesday?

BenzingaOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

2 Pa. pharmaceutical facilities to close, lay off 173 people

PennLive.comOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Binghamton University research study advances treatment for Duchenne muscular dystrophy

Binghamton UniversityOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Federal Drug Research Profits: Taxpayers Get Little Return

Legis1Original source

🌍Jun 30discoverynews.google.comTier 2 · Trade media

Medical journal retracts Tavneos pivotal study article, complicating Amgen’s defense effort

Fierce PharmaOriginal source

🌍Jun 30discoverynews.google.comTier 2 · Trade media

BIO outshines World Cup as biotech celebrates 50th anniversary with a ‘call to action’

BioSpaceOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

VistaGen Therapeutics, Inc. (VTGN) announced topline data and post-hoc analysis results from the Phase 3 clinical trial Palisade-4 of its candidate drug Fasedienol for the acute treatment of social anxiety disorder.

BitgetOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Moleculin Biotech, Inc. (Moleculin) recently announced the interim analysis results of its phase 2/3 "Miracle" clinical trial, showing positive data.

BitgetOriginal source

🌍Jun 30discoverynews.google.comTier 2 · Trade media

Abivax rebounds from stock drop with safety data for much-hyped colitis prospect

Fierce BiotechOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Unicycive gets FDA CRL for OLC kidney drug application

grafa.comOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Unicycive gets FDA CRL for OLC kidney drug application

grafa.comOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Baltimore Ravens TE Mark Andrews Reveals New Partnership Biotech Company to Raise Awareness

Sports IllustratedOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Tsingke Biotech Hosts Shanghai Salon on Oligonucleotide Drugs, Spotlighting Next-Gen RNA Therapeutics

PR NewswireOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

FDA Chooses 7 Companies for PreCheck Pilot

PharmTech.comOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

US FDA declines to approve Unicycive's kidney disease drug

ReutersOriginal source

🌍Jun 30discoverynews.google.comTier 2 · Trade media

Vistagen fails another phase 3 social anxiety trial but spies path to market

Fierce BiotechOriginal source

🌍Jun 30discoverynews.google.comTier 2 · Trade media

Investors double down on Bain-backed startup

statnews.comOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Documentation Reliability Across Contractors: A Quality Systems Approach

PharmTech.comOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity

24/7 Wall St.Original source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Medicare Obesity Drug Coverage Puts These 3 Biotech Stocks In Focus

simplywall.stOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Is MapLight Therapeutics, Inc. (MPLT) Stock a Biotech Opportunity Ahead of the ZEPHYR Trial Readout?

Yahoo Finance UKOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.

Pharma VoiceOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Is Takeda Pharmaceutical Company Limited (TAK) Stock Positioned for Growth After Strong LATITUDE Atlas Study Data?

Yahoo FinanceOriginal source

🌍Jun 30discoverynews.google.comTier 3 · Aggregated media

Is Teva Pharmaceutical Industries Limited (TEVA) Stock Undervalued After Recent Pullback and Vitiligo Program Update?

Yahoo FinanceOriginal source